Open Access. Powered by Scholars. Published by Universities.®
Dietetics and Clinical Nutrition Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Dietetics and Clinical Nutrition
Cardiometabolic Risk Factors Efficacy Of Semaglutide In The Step Program, Anastassia Amaro, Neil S. Skolnik, Danny Sugimoto
Cardiometabolic Risk Factors Efficacy Of Semaglutide In The Step Program, Anastassia Amaro, Neil S. Skolnik, Danny Sugimoto
Abington Jefferson Health Papers
People with overweight or obesity often suffer from associated cardiometabolic diseases and comorbidities. Current therapies for obesity include lifestyle intervention, bariatric surgery, and pharmacotherapy. The magnitude of weight loss achieved with these therapies can determine the level of improvement in various comorbidities. Once-weekly subcutaneous semaglutide 2.4 mg is a glucagon-like peptide-1 receptor agonist recently approved by the US Food and Drug Administration for the treatment of obesity. This article reviews data from the global phase 3 Semaglutide Treatment Effect in People with obesity (STEP) program, comparing the efficacy of once-weekly subcutaneous semaglutide 2.4 mg versus placebo for weight loss and …